The acquisition grows Medtronic’s ENT portfolio with the Propel and Sinuva product lines, according to a May 13 news release. Intersect ENT’s subsidiary company, Fiagon, was not included in the acquisition.
The $1.1 billion acquisition was announced in August.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.